Research
Hormonal
Propionate, a short-chain fatty acid produced from carbohydrate fermentation, can inhibit the conversion of acetate to cholesterol and fat, potentially reducing intra-abdominal tissue accretion and intrahepatocellular lipid content in overweight adults.
Foods that promote the production of propionate (a type of SCFA) in the gut may help manage body fat and liver fat levels. This suggests that the type of fiber you eat matters for metabolic health, not just total fiber intake.
ModerateSupportsMEDIUM confidence
propionate can inhibit the conversion of acetate to cholesterol and fat... propionate administration alone can reduce intra-abdominal tissue accretion and intrahepatocellular lipid content in overweight adults
Why this rating
Based on a review citing specific studies (e.g., [67]), but the review itself is not a primary clinical trial.
Source
Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health
Kaitlyn Oliphant et al. · Microbiome · 2019
DOI 10.1186/s40168-019-0704-8
narrative_reviewCited 1,339×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Short-chain fatty acids (SCFAs), particularly butyrate, acetate, and propionate, produced by gut microbiota fermentation of dietary carbohydrates, provide significant caloric energy to the host and exert anti-inflammatory effects by promoting intestinal epithelial integrity and inducing regulatory T cells.Good
- Excessive protein fermentation by gut microbiota can produce toxic metabolites such as hydrogen sulfide, ammonia, and certain amines, which may damage the intestinal epithelium, promote inflammation, and are associated with diseases like inflammatory bowel disease (IBD).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →